Hunt Henry, Fadly Aly, Silva Robert, Zhang Huanmin
United States Department of Agriculture, Agriculture Research Service, Avian Disease and Oncology Laboratory, 3606 East Mount Hope Road, East Lansing, MI 48823, USA.
Avian Dis. 2008 Sep;52(3):433-40. doi: 10.1637/8183-112907-Reg.1.
Endogenous avian leukosis virus (ALVE) and the ALVE receptor (TVBS1) status of six commercial chicken lines supplying specific-pathogen-free eggs were analyzed. All commercial chicken lines are certified free of the avian leukosis virus (ALV) by screening for expression of the p27 protein using the standard enzyme-linked immunosorbent assay. The commercial chicken lines A, E, and F contained replication competent ALVE inserts. Line A was fixed for ALVE21, and lines E and F were segregating for ALVE10. In addition, ALVE1 was detected in all the chicken lines. Chicken lines B, D, and F were essentially fixed for the TVBS1 allele that confers susceptibility to ALVE, whereas lines A, C, B, and E were resistant, containing either the TVBS3 or TVBR alleles. The results show that lines selected to be ALV p27 negative give rise to two different genotypes. One genotype lacks the TVBS1 receptor for ALVE. Chicken lines with the TVBS1 negative genotype can retain replication competent endogenous virus inserts such as ALVE2, 10, or 21 and still display the p27 negative phenotype. These replication competent ALVE viruses are phenotypically p27 negative in the absence of the TVBS1 receptor because their chromosomal integration sites restrict transcription and subsequent production of the p27 protein and virus particles to levels below the detection limit. If the TVBS1 receptor is present, the limited production of ALVE virus particles reinfects and integrates into more productive chromosomal locations in the cell. Increased production of infective virus particles and detectable levels of p27 follow this reinfection and integration into more active regions of the cells genome. The other genotype observed in the commercial lines retains the ALVE receptor (TVBS1) but either lacks replication competent inserts or expresses the envelope encoded protein from defective inserts such as ALVE3 or ALVE6. In this phenotype, the env-coded glycoprotein encoded by the defective inserts binds to the TVBS1 receptor and blocks the reinfection of the replication competent ALVE virus. This receptor interference stops reinfection and subsequent production of detectable virus particles and the p27 protein. Mixtures of different p27 negative phenotypes can result in the p27 positive phenotype and ALVE virus production. For example, mixtures of ALVE receptor positive (TVB*S1) but ALVE negative (p27 negative and envelope negative) chick embryo fibroblasts (CEFs) with fibroblasts that are receptor negative but ALVE positive could generate cells expressing high levels of p27 and ALVE virus. In this situation, the undetectable levels of ALVE virus from the receptor negative CEFs would infect and integrate into the receptor positive CEFs and produce detectable levels of ALVE virus. The implications of these findings for vaccine manufacturers and regulatory agencies are discussed.
对六个供应无特定病原体鸡蛋的商业鸡品系的内源性禽白血病病毒(ALVE)及ALVE受体(TVBS1)状态进行了分析。所有商业鸡品系通过使用标准酶联免疫吸附测定法筛选p27蛋白的表达,均被认证为无禽白血病病毒(ALV)。商业鸡品系A、E和F含有具有复制能力的ALVE插入片段。品系A固定为ALVE21,品系E和F则为ALVE10的分离状态。此外,在所有鸡品系中均检测到ALVE1。鸡品系B、D和F基本上固定为对ALVE易感的TVBS1等位基因,而品系A、C、B和E具有抗性,含有TVBS3或TVBR等位基因。结果表明,被选为ALV p27阴性的品系产生了两种不同的基因型。一种基因型缺乏ALVE的TVBS1受体。具有TVBS1阴性基因型的鸡品系可以保留具有复制能力的内源性病毒插入片段,如ALVE2、10或21,并且仍表现出p27阴性表型。这些具有复制能力的ALVE病毒在没有TVBS1受体的情况下在表型上为p27阴性,因为它们的染色体整合位点将转录以及随后p27蛋白和病毒颗粒的产生限制在检测限以下。如果存在TVBS1受体,ALVE病毒颗粒的有限产生会重新感染并整合到细胞中更具生产性的染色体位置。感染性病毒颗粒产量的增加以及p27可检测水平会随着这种重新感染并整合到细胞基因组的更活跃区域而出现。在商业品系中观察到的另一种基因型保留了ALVE受体(TVBS1),但要么缺乏具有复制能力的插入片段,要么表达来自缺陷插入片段(如ALVE3或ALVE6)的包膜编码蛋白。在这种表型中,由缺陷插入片段编码的env编码糖蛋白与TVBS1受体结合,并阻止具有复制能力的ALVE病毒的重新感染。这种受体干扰阻止了重新感染以及随后可检测到的病毒颗粒和p27蛋白的产生。不同p27阴性表型的混合物可导致p27阳性表型和ALVE病毒产生。例如,ALVE受体阳性(TVB*S1)但ALVE阴性(p27阴性且包膜阴性)的鸡胚成纤维细胞(CEF)与受体阴性但ALVE阳性的成纤维细胞的混合物可产生表达高水平p27和ALVE病毒的细胞。在这种情况下,来自受体阴性CEF的不可检测水平的ALVE病毒会感染并整合到受体阳性CEF中,并产生可检测水平的ALVE病毒。讨论了这些发现对疫苗制造商和监管机构的影响。